Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elgene Lim

Showing results (111-120 of 130) with videos related to

Pageof 13
Sort By:
Nature Medicine|January 19, 2021
The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancerTheresa E Hickey, Luke A Selth, Kee Ming Chia, et al.
Nature Structural & Molecular Biology|January 5, 2024
The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancerJoanna Achinger-Kawecka, Clare Stirzaker, Neil Portman, et al.
Cell Reports|September 22, 2021
DNA methylation is required to maintain both DNA replication timing precision and 3D genome organization integrityQian Du, Grady C Smith, Phuc Loi Luu, et al.
Cell Reports|November 24, 2016
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast CancerShawn F Johnson, Cristina Cruz, Ann Katrin Greifenberg, et al.
Lancet (London, England)|April 22, 2023
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trialFabrice André, Yeon Hee Park, Sung-Bae Kim, et al.
Genome Medicine|May 11, 2021
Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysisSunny Z Wu, Daniel L Roden, Ghamdan Al-Eryani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2024
Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast CancerCristina Guarducci, Agostina Nardone, Douglas Russo, et al.
Nature Communications|July 26, 2018
Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancerAurélie S Cazet, Mun N Hui, Benjamin L Elsworth, et al.
Breast Cancer Research : BCR|June 13, 2020
Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancerLaura A Baker, Holly Holliday, Daniel Roden, et al.
The EMBO Journal|August 14, 2020
Stromal cell diversity associated with immune evasion in human triple-negative breast cancerSunny Z Wu, Daniel L Roden, Chenfei Wang, et al.
Pageof 13

Showing results (111-120 of 130) with videos related to

Sort By:
Pageof 13
Nature Medicine|January 19, 2021
The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancerTheresa E Hickey, Luke A Selth, Kee Ming Chia, et al.
Nature Structural & Molecular Biology|January 5, 2024
The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancerJoanna Achinger-Kawecka, Clare Stirzaker, Neil Portman, et al.
Cell Reports|September 22, 2021
DNA methylation is required to maintain both DNA replication timing precision and 3D genome organization integrityQian Du, Grady C Smith, Phuc Loi Luu, et al.
Cell Reports|November 24, 2016
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast CancerShawn F Johnson, Cristina Cruz, Ann Katrin Greifenberg, et al.
Lancet (London, England)|April 22, 2023
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trialFabrice André, Yeon Hee Park, Sung-Bae Kim, et al.
Genome Medicine|May 11, 2021
Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysisSunny Z Wu, Daniel L Roden, Ghamdan Al-Eryani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2024
Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast CancerCristina Guarducci, Agostina Nardone, Douglas Russo, et al.
Nature Communications|July 26, 2018
Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancerAurélie S Cazet, Mun N Hui, Benjamin L Elsworth, et al.
Breast Cancer Research : BCR|June 13, 2020
Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancerLaura A Baker, Holly Holliday, Daniel Roden, et al.
The EMBO Journal|August 14, 2020
Stromal cell diversity associated with immune evasion in human triple-negative breast cancerSunny Z Wu, Daniel L Roden, Chenfei Wang, et al.
Pageof 13